BridgeBio granted Perform rating at Oppenheimer on market challenges [Seeking Alpha]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Seeking Alpha
With the FDA expected to decide on a marketing nod for acoramidis in a heart condition called ATTR amyloidosis with cardiomyopathy (ATTR-CM) by late November, Oppenheimer analyst Trevor Allred argued that an approval "seems less than certain." Allred also notes that if approved, acoramidis will have to compete against a rival product from Pfizer ( PFE ) and a potential new entrant from Alnylam Pharmaceuticals ( ALNY ) without much differentiation. The analyst also pointed to low-cost generics expected to enter by 2029. "Pfizer and Alnylam are two competitors with far more sales experience and breadth and are far better capitalized than BBIO," he added. The analyst said that despite its best-in-class potential against a bone disorder called achondroplasia, infigratinib is positioned to enter a competitive market. Limitations in IP rights linked to the asset were among his other concerns. Recommended For You Comments More Trending News Recommended For You More Trending
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Here's Why You Should Add ALNY Stock to Your Portfolio Right Now [Yahoo! Finance]Yahoo! Finance
- Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund's Performance [Yahoo! Finance]Yahoo! Finance
- Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024Business Wire
- Alnylam to Webcast TTR Investor DayBusiness Wire
ALNY
Earnings
- 8/1/24 - Beat
ALNY
Sec Filings
- 10/3/24 - Form 4
- 10/3/24 - Form 3
- 8/22/24 - Form 4
- ALNY's page on the SEC website